IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Severine Vermeire  ¹     Bruce E. Sands  ²     Laurent Peyrin-Biroulet  ^{3, 4}     Geert R. D'Haens  ⁵     Julian Panés  ⁶     Andres Yarur  ⁷     Doug Wolf  ⁸     Timothy Ritter  ⁹     Stefan Schreiber  ¹⁰     Kevin Shan  ¹¹     Chris Rabbat  ¹²     Michael Chiorean  ¹³     Filip Baert  ¹⁴     Marla C. Dubinsky  ¹⁴     Martina Goetsch  ¹⁵     Silvio Danese  ¹⁶     Brian G. Feagan  ^{17, 18    
1} University Hospital Leuven, Leuven, Belgium
² Icahn School of Medicine at Mount Sinai, New York, United States
³ University of Lorraine, CHRU-Nancy, Nancy, France
⁴ University of Lorraine, Inserm, NGERE, Nancy, France
⁵ Amsterdam University Medical Centers, Amsterdam, Netherlands
⁶ Formerly of Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁷ Cedars-Sinai Medical Center, Los Angeles, United States
⁸ Atlanta Gastroenterology Associates, Atlanta, United States
⁹ GI Alliance, Southlake, United States
¹⁰ University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
¹¹ Pfizer Inc, San Diego, United States
¹² Pfizer Inc, New York, United States
¹³ Swedish Medical Center, Seattle, United States
¹⁴ AZ Delta Deltalaan 2, Roeselare, Belgium
¹⁵ Pfizer AG, Zürich, Switzerland
¹⁶ IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
¹⁷ Western University, London, Canada
¹⁸ Alimentiv Inc, London, Canada

Topic
IBD

Session
Sequential therapies in IBD: Raising the bar

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)